Radiation Oncology Book from C.H.I.P.S.

New Therapeutic Agents in Thrombosis and Thrombolysis
Third Edition
by Jane E. Freedman

As the number of patients with thrombosis and thrombolysis increases, there is a critical need for clinicians to learn the latest scientific discoveries and treatment options.

New Therapeutic Agents in Thrombosis and Thrombolysis is a comprehensive text for cardiologists, hematologists, and pharmacologists in need of a resource on current agent development technology for treating cardiovascular and thromboembolic diseases.


  • a thorough examination of all the agents involved in treating thrombosis
  • chapters on biomarkers, testing, and pharmacogenomics
  • key topics, including new targets for antithrombotics, the development of novel classes of platelet inhibitors, new thrombolytic therapies, and evolving clinical uses of thrombolytics for ischemic stroke and venous thrombosis
  • the hemostatic and thrombotic pathways


Overview of the Investigation and Regulation and Thrombosis

  1. Overview of Hemostasis and Fibrinolysis
  2. Overview of Platelet-dependent Thrombosis
  3. Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents
  4. Pharmacogenomics of Warfarin Anticoagulation
  5. Pharmacogenomics of Platelet Inhibitors
  6. The Effects of Antiplatelet, Antithrombotic and Fibrinolytic Agents in Circulating Biomarkers
  7. The Role of Platelet Function Testing in the Development of Platelet Inhibitors
  8. The Role of Proteomics and Transcriptomics in the Development of Antithrombotics
New Heparins, Thrombin Inhibitors, and Antithrombotics
  1. Overview of New Anticoagulant Drugs
  2. Anticoagulants for the Treatment of Venous Thromboembolism
  3. Anticoagulation in Acute Coronary Syndromes
  4. Anticoagulation in Pregnancy
  5. Anticoagulants in Cancer
  6. Anticoagulation in Children
  7. New Heparins: Synthetic Pentasaccharides
  8. Treatment of Heparin-induced Thrombocytopenia
  9. Emerging Links Between Thombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low Molecular Weight Heparins
  10. Oral Direct Factor Xa Inhibitors
  11. Direct Thrombin Inhibitiors
  12. Modulators of the Protein C Pathway
  13. Factor IXa Inhibitors
  14. Contact Activation Pathways as Targets for New Anticoagulants
New Antiplatelet Agents
  1. Overview of Antiplatelet Therapy
  2. Markers of Platelet Function
  3. Intravenous Glyoprotein IIb/IIIa Receptor Antagonists
  4. Inhibitors of Platelet Adhesion: VWF-GP1b/IX and Collagen-GPVI Inhibitors
  5. Three Generations of Thienopyridines: Ticlopidone, Clopidogrel, and Prasugrel
  6. Direct Inhibitors of P2Y12 Antagonists
  7. Nitric Oxide Donors as Platelet Inhibitors
  8. The Inter-relationships of Thrombin and Platelets: The Protease Activated Receptor-1 (PAR-1)
  9. Other Antiplatelet Agents
  10. The Combination of Anticoagulants and Platelet Inhibitors Post-Coronary Stent Implantation
New Thrombolytic Agents and Indications
  1. Overview of Established and New Thrombolytics
  2. Thrombolysis of Deep Vein Thrombosis
  3. Thrombolysis for Acute Pulmonary Embolism
  4. Acute Thrombolysis in Ischemic Cerebrovascular Disease
  5. Fibrinolysis for Acute Myocardial Infarction
  6. Epilogue: The Evolution of Therapeutic Management of Thrombotic and Cardiovascular Disease

click here to see books of related interest


New Therapeutic Agents in Thrombosis and Thrombolysis
Third Edition
by Jane E. Freedman

2009 700 pages $289.95 + shipping
Texas residents please add 6.75 % sales tax

Go to Top of Page

copyright © 1997-2010 Culinary and Hospitality Industry Publications Services